+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study



Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study



Transplant Infectious Disease 13(2): 136-144



The objectives of this epidemiological, prospective study were to describe the characteristics of cytomegalovirus (CMV) infection in heart transplant (HT) recipients and to identify the variables that may influence the development of CMV viremia and CMV disease in these patients. HT recipients ≥18 years of age (n=199) were included in the study. Variables studied included CMV serostatus, immunosuppressive treatment, and administration of anti-CMV prophylaxis. The mean age of the population was 52 years, and 84% were males. Immunosuppressive regimens were administered as induction therapy to 92.5% of patients; 88.5% of patients received calcineurin inhibitors as maintenance therapy. Anti-CMV treatment was given to 59% of 199 patients as prophylaxis (70%), preemptive therapy (10%), or to treat CMV infection (20%). Overall, 43% of patients had at least 1 positive viremia test. No patient with a high-risk serostatus (donor+/recipient-) receiving prophylaxis developed CMV syndrome, and only 2.5% of 199 patients developed CMV invasive disease. Multivariate analysis showed that having a positive donor CMV serostatus was associated with an increased risk of developing CMV viremia (P<0.012), while use of mammalian target of rapamycin (mTOR) inhibitors was associated with a decreased risk (P=0.005). In a population of HT recipients, the CMV infection rate was similar to that seen in previous studies, but the progression to overt CMV disease was very low. Having a CMV-positive donor was identified as an independent risk factor for developing CMV viremia, while the use of mTOR inhibitors was protective against viremia.

(PDF emailed within 0-6 h: $19.90)

Accession: 055579601

Download citation: RISBibTeXText

PMID: 21040280

DOI: 10.1111/j.1399-3062.2010.00573.x


Related references

Prospective study of the incidence, timing, significance, risk factors, and outcome of cytomegalovirus infection in liver transplant patients with double-drug immunosuppression and no prophylactic antiviral therapy. Transplantation Proceedings 25(2): 1786, 1993

Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group. Journal of Heart and Lung Transplantation 13(3): 394-404, 1994

Cytomegalovirus infection in heart lung transplant recipients risk factors clinical associations and response to treatment. Journal of Infectious Diseases 164(6): 1045-1050, 1991

Cytomegalovirus infection negatively influences coronary remodeling modalities in heart transplant recipients A prospective Study. Journal of the American College of Cardiology 41(6 Supplement A): 186A, March 19, 2003

Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplantation Proceedings 38(6): 1922-1923, 2006

Post-renal transplant cytomegalovirus infection: study of risk factors. Transplantation Proceedings 44(3): 706-709, 2012

Pre-transplant risk factors predicting post-transplant cytomegalovirus infection in liver transplant recipients. Transplant International 20(5): 419-424, 2007

Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: A single centre, prospective cohort study. Journal of Clinical Virology 68: 37-42, 2016

Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 55(4): 851-857, 1993

Cytomegalovirus infection and disease in renal transplant patients treated with cyclosporin. A prospective study. Transplant International 2(2): 92-95, 1989

A prospective assessment of cytomegalovirus immune evasion gene transcription profiles in transplant patients with cytomegalovirus infection. Transplantation 83(9): 1200-1206, 2007

Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study. Transplant Infectious Disease 19(3), 2017

Risk Factors for Congenital Cytomegalovirus Infection Following Primary and Nonprimary Maternal Infection: A Prospective Neonatal Screening Study Using Polymerase Chain Reaction in Saliva. Clinical Infectious Diseases 65(3): 398-404, 2017

Cytomegalovirus infection rate among heart transplant patients in relation to the potency of antithymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group. Transplantation Proceedings 26(3): 1718, 1994

The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction. Qjm 91(10): 667-676, 1999